Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IGF-methotrexate conjugate - IGF Oncology

Drug Profile

IGF-methotrexate conjugate - IGF Oncology

Alternative Names: 765-IGF-MTX; IGF-MTX; IGF/MTX; Insulin-like-growth-factor-methotrexate-conjugate

Latest Information Update: 10 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IGF Oncology
  • Developer IGF Oncology; University of Chicago
  • Class Antineoplastics; Benzamides; Drug conjugates; Glutamates; Growth factors; Peptides; Pterins; Small molecules; Somatomedins
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes; Myeloid leukaemia
  • No development reported Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 21 Feb 2018 Phase-I/II clinical trials in Myelodysplastic syndromes (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT03175978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top